Femasys Initiates Enrollment In Pivotal Trial Of Its Permanent Birth Control Candidate FemBloc
Femasys Initiates Enrollment In Pivotal Trial Of Its Permanent Birth Control Candidate FemBloc
Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting women's unmet needs worldwide by developing a broad portfolio of innovative product candidates and products that include minimally invasive, in-office technologies for reproductive health, announced the initiation of enrollment in a prospective multi-center pivotal trial for FemBloc INtratubal Occlusion for TranscervicAL PErmanent Birth Control (the "FINALE" trial), to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc. The robust trial is designed to address the high unmet need that exists for women seeking permanent birth control for whom elective surgery remains the only option.
Femasys Inc.（納斯達克股票代碼：FEMY）是一家生物醫學公司，致力於通過開發廣泛的創新候選產品和產品（包括微創的辦公室內生殖健康技術）來滿足全球女性未得到滿足的需求。該公司宣佈開始參加一項前瞻性的多中心關鍵試驗 Fembloc 在Transcervic 的 tratubal OcclusionAL PErmanent Birth Control（“FINALE” 試驗），旨在調查其研究性永久節育候選藥物FemBloc的安全性和有效性。這項強有力的試驗旨在解決尋求永久節育措施的女性存在的高未滿足需求，而選擇性手術仍然是唯一的選擇。